The NM_000152.5:c.896T>C variant in GAA is a missense variant predicted to cause substitution of Leucine by Proline at amino acid 299 (p.Leu299Pro). At least 4 individuals have been reported with this variant and either diagnosis of Pompe disease with ERT treatment or GAA activity <10% normal in lymphocytes/leukocytes/muscle samples/unknown tissue (PMIDs 26622091, 26873529, 25626711,29422078). Another patient was homozygous for this variant and identified by newborn screening for Pompe disease (PMID: 22133539). This meets the criteria for PP4_Moderate. This variant has been detected in at least 7 individuals with Pompe disease or identified by newborn screening for Pompe disease. Of those individuals, 4 were compound heterozygous for the variant and a pathogenic variant, c.-32-13T>G (PMID:18757064, 26622091, 26873529). At least 1 individual was homozygous for the variant (PMID: 22133539,25626711). Criteria for PM3 were met. This variant is absent in gnomAD v2.1.1 (PM2_Supporting). Expression of the variant in COS cells resulted in 0% wild type GAA activity and evidence of abnormal synthesis and processing on Western blots leading the variant to be described as Class B (“potentially less severe”, indicating that this variant may impact protein function (PMID:18425781)(PS3). REVEL Score = 0.952 which is higher than the LSD VCEP threshold for PP3 (>0.7) and therefore meets this criterion. There is a ClinVar entry for this variant (Variation ID: 180144, 2 star review status) with 5 submitters classifying the variant as Pathogenic. In summary, this variant meets the criteria to be classified as Pathogenic for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Storage Disorders Variant Curation Expert panel (specifications Version 2.0): PS3, PP4_Moderate, PM3, PM2_Supporting, PP3